Abstract
Non-alcoholic fatty liver disease is regarded as the hepatic manifestation of metabolic syndrome and is an important and common cause of chronic liver disease with a potential to develop end-stage liver disease. While important advances in the pathophysiology have been achieved using genetically modified and diet-induced animal models, in-vitro models have been only recently proposed. These models include primary culture and immortalized cell lines. Here we critically review the characteristics of the in vitro models described, the advantages and limitations of the in vitro approach, and the results derived.
Keywords: Fatty acids, fatty liver, biomedical research, biological models, Non-alcoholic, hepatic manifestation, metabolic syndrome, end-stage liver disease, diet-induced animal models
Current Medicinal Chemistry
Title: In Vitro Models for the Study of Non-Alcoholic Fatty Liver Disease
Volume: 18 Issue: 7
Author(s): N. C. Chavez-Tapia, N. Rosso and C. Tiribelli
Affiliation:
Keywords: Fatty acids, fatty liver, biomedical research, biological models, Non-alcoholic, hepatic manifestation, metabolic syndrome, end-stage liver disease, diet-induced animal models
Abstract: Non-alcoholic fatty liver disease is regarded as the hepatic manifestation of metabolic syndrome and is an important and common cause of chronic liver disease with a potential to develop end-stage liver disease. While important advances in the pathophysiology have been achieved using genetically modified and diet-induced animal models, in-vitro models have been only recently proposed. These models include primary culture and immortalized cell lines. Here we critically review the characteristics of the in vitro models described, the advantages and limitations of the in vitro approach, and the results derived.
Export Options
About this article
Cite this article as:
C. Chavez-Tapia N., Rosso N. and Tiribelli C., In Vitro Models for the Study of Non-Alcoholic Fatty Liver Disease, Current Medicinal Chemistry 2011; 18 (7) . https://dx.doi.org/10.2174/092986711794940842
DOI https://dx.doi.org/10.2174/092986711794940842 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Natural Alpha-Glucosidase Inhibitors: Therapeutic Implication and Structure- Activity Relation Ship
Letters in Drug Design & Discovery Lectin-Like Oxidized Low Density Lipoprotein Receptor 1 (LOX-1) in Atherogenesis: A Brief Review
Current Medicinal Chemistry Evaluation of Eudragit® Retard Polymers for the Microencapsulation of Alpha-Lipoic Acid
Current Drug Delivery Modulation of Cardiovascular Remodeling with Statins: Fact or Fiction?
Current Vascular Pharmacology Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective
Current Pharmaceutical Design Insulin Secretagogues, Sulfonylurea Receptors and KATP Channels
Current Pharmaceutical Design Diabetes, Cognitive Function, and the Blood-Brain Barrier
Current Pharmaceutical Design Treatment of Diabetic Cardiovascular Autonomic, Peripheral and Painful Neuropathy. Focus on the Treatment of Cardiovascular Autonomic Neuropathy with ACE Inhibitors
Current Vascular Pharmacology Nanoparticles Functionalized with Venom-Derived Peptides and Toxins for Pharmaceutical Applications
Current Pharmaceutical Biotechnology Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing- Remitting Multiple Sclerosis
Current Pharmaceutical Design Effects of Mulberry on The Central Nervous System: A Literature Review
Current Neuropharmacology Tetrahydrobiopterin Biosynthesis, Utilization and Pharmacological Effects
Current Drug Metabolism The Perfect Storm: A Rheumatologist's Point of View on COVID-19 Infection
Current Rheumatology Reviews Long Term Cardiovascular Risk in Women
Vascular Disease Prevention (Discontinued) Endothelin Receptors, Mitochondria and Neurogenesis in Cerebral Ischemia
Current Neuropharmacology Genomics and the Prospects of Existing and Emerging Therapeutics for Cardiovascular Diseases
Current Pharmaceutical Design The Management of Phosphodiesterase-5 (PDE5) Inhibitor Failure
Current Vascular Pharmacology Glia-Driven Neuroinflammation and Systemic Inflammation in Alzheimer’s Disease
Current Neuropharmacology The Renin Angiotensin System in the Regulation of Angiogenesis
Current Pharmaceutical Design Pharmacological Treatment of Obesity, Food Intake, and Reversal of Metabolic Disorders
Current Nutrition & Food Science